Use of Endocrine Therapy for Breast Cancer Risk Reduction
Introduction
Introduction
Diagnosis
...Dia...
...1. Breast Cancer Risk Assessment Tool...
Treatment
...Treatm...
...Table 2. Summ...
...Tamoxif...
...d be discussed as an option to reduce the r...
...ecommended for use in women with a histor...
...nded for women who are pregnant, women who may be...
...recommended in combination with hormone thera...
...should include a timely work-up of abnormal...
Discussions with patients and health car...
...E: 20 mg/d orally for 5 years. (EB, S)7251...
...ng evidence-based on 5 RCTs with low risk of...
...Raloxifene...
...be discussed as an option to reduce the risk of i...
...ed longer than 5 years in women with oste...
...NOT be used for BC risk reduction in pre...
...s NOT recommended for use in women with a hi...
...cussions with patients and health car...
...GE: 60 mg/d orally for 5 years. (EB, S...
...idence-based on 4 RCTs with low risk of bias)...
...e discussed as an alternative to tamox...
...d NOT be used for BC risk reductio...
...scussions with patients and health care pr...
...E: 25 mg/d orally for 5 years. (EB...
...nce-based on 1 RCT with low risk of bias)...
...Anastrozole...
...e (1 mg/day orally for 5 years) should be...
...most likely to benefit are those with one of more...
...d NOT prescribe anastrozole, exemestane or...
...een patients and health care provi...
...tiating an aromatase inhibitor, clinicians shou...
...s should inform women also of the possibility of j...
...outweigh harms; Evidence quality: high;...
...ummary of Agent Indications Agent...
...4. Adverse Effects of Endocrine Therapy...